Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CNSP 
Cns Pharmaceuticals Inc (CNSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CNSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -63.68% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.28M USD | Price to earnings Ratio - | 1Y Target Price 0.5 |
Price to earnings Ratio - | 1Y Target Price 0.5 | ||
Volume (30-day avg) 472790 | Beta 1.05 | 52 Weeks Range 1.21 - 795.00 | Updated Date 03/30/2025 |
52 Weeks Range 1.21 - 795.00 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -352.97 |
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -224% | Return on Equity (TTM) -1018.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4889914 | Price to Sales(TTM) - |
Enterprise Value -4889914 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 40746400 | Shares Floating 31426967 |
Shares Outstanding 40746400 | Shares Floating 31426967 | ||
Percent Insiders 1.21 | Percent Institutions 0.7 |
Analyst Ratings
Rating 4 | Target Price 0.5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cns Pharmaceuticals Inc
Company Overview
History and Background
Cns Pharmaceuticals Inc. does not exist as a publicly traded company in the United States. Therefore, a historical background cannot be provided.
Core Business Areas
Leadership and Structure
Cns Pharmaceuticals Inc. does not exist as a publicly traded company in the United States. Therefore, information about leadership and structure cannot be provided.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Since Cns Pharmaceuticals Inc. does not exist, providing an industry overview related to it is not possible.
Positioning
Since Cns Pharmaceuticals Inc. does not exist, providing its positioning within an industry is not possible.
Total Addressable Market (TAM)
Since Cns Pharmaceuticals Inc. does not exist, its position in the total addressable market cannot be determined.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Cns Pharmaceuticals Inc. does not exist as a publicly traded company in the United States. Therefore, a competitive landscape evaluation cannot be performed.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Cns Pharmaceuticals Inc. does not exist as a publicly traded company in the United States. Therefore, historical growth cannot be provided.
Future Projections: Cns Pharmaceuticals Inc. does not exist as a publicly traded company in the United States. Therefore, future projections cannot be provided.
Recent Initiatives: Cns Pharmaceuticals Inc. does not exist as a publicly traded company in the United States. Therefore, recent initiatives cannot be provided.
Summary
Cns Pharmaceuticals Inc. is not a publicly traded company in the United States, and therefore, no analysis can be performed on its financial health, market position, or growth prospects. Consequently, any assessment of its strengths, weaknesses, opportunities, or threats is not possible. The absence of publicly available data prevents a comprehensive evaluation.
Similar Companies
Sources and Disclaimers
Data Sources:
- Publicly available databases for US Stock Markets
Disclaimers:
The analysis is based on the premise that Cns Pharmaceuticals Inc. is a publicly traded US company. Since it's not, the analysis is largely based on the lack of available information. If the company exists privately, this analysis is not relevant.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2019-11-08 | CEO, President & Director Mr. John Michael Climaco Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.cnspharma.com |
Full time employees 3 | Website https://www.cnspharma.com | ||
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.